Heart pump for severe heart failure and shock
Part of Heart & circulation clinical trials.
This trial is testing whether a temporary heart pump (Impella) can help people with severe heart failure and cardiogenic shock (when the heart can't pump enough blood). The goal is to see if this device can reduce fluid buildup and improve blood flow, but it's for people who are very ill and need extra support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have heart failure with a weak heart pump (ejection fraction of 35% or less).
- You must have signs of fluid buildup (like swelling or fluid in the lungs) and signs of cardiogenic shock (low blood pressure or poor blood flow).
- You must be getting medicines to help your blood pressure or heart pump.
- You cannot have a recent heart attack (within 30 days), a stroke or TIA (within 90 days), or a cardiac arrest.
- You cannot be on dialysis for kidney failure, have an active infection, or have a bleeding risk that makes a heart pump device unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people in the intensive care unit who are using a heart pump called Impella. It will collect information about how well the heart pumps blood during treatment to help doctors learn more.
This study tests whether a special heart pump (Impella 5.5) can help patients with severe heart failure (cardiogenic shock) safely start and increase their heart failure medications. The goal is to see if this approach can help the heart recover and improve outcomes.
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
This trial tests a new heart pump device (CorVad) to support the heart in people who are in cardiogenic shock after a heart attack. It may help stabilize blood pressure and improve blood flow, potentially giving the heart time to recover.
This study reviews how well people tolerated the Impella heart pump during cardiogenic shock and what complications occurred. It looks at past cases from 2010 to 2022 to help doctors understand the safety of this device.
This study looks at when to insert a small heart pump (Impella CP) in people who have had a heart attack and are in cardiogenic shock, a condition where the heart can't pump enough blood. The goal is to find out if placing the pump before or after the artery-opening procedure improves outcomes.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.